Atlas Trials

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Clinical trial NCT02974647 · RECRUITING

Trial details

NCT number
NCT02974647
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2016-11-01
Primary completion
2027-11-01
Enrollment
83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.